Novartis’ Zykadia more effective than chemo, new study shows
October 13, 2016Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Alcensa, Novartis, Roche, Xalkori, ceritinib, crizotinib, lung cancer, zykadia
Phase III results for Novartis’ cancer drug Zykadia (ceritinib) have revealed it as more effective than chemo at halting progression …
Nestlé appoints Paul Navarre as CEO of Nestlé Skin Health
October 12, 2016Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Allergan, Nestle skin health, Paul Navarre, nestle
The announcement of Paul Navarre’s appointed as CEO of Nestlé Skin Health was announced on 11 October. He will take …
Tesaro’s ovarian cancer drug success threatens market rivals
October 12, 2016Research and Development AbbVie, AstraZeneca, Pfizer, Roche, Tesaro, avastin, lynparza, niraparib, talazoparib, veliparib
Phase III results from Tesaro’s niraparib PARP inhibitor could spell trouble for rivals Roche and AstraZeneca as its showed sizeable …
Gamida Cell receives Breakthrough Therapy Designation from FDA
October 12, 2016Research and Development Breakthrough Therapy Designation, FDA, Gamida Cell, leukaemia, lymphoma
Gamida Cell have been granted a Breakthrough Therapy Designation for their NiCord drug. NiCord has already passed through Phase I …
Transgene announce key partnership with Merck KGaA and Pfizer
October 12, 2016Research and Development Cancer, France, Merck Group, Pfizer, Transgene, avelumab, head, neck
Transgene, a company that designs and developed targeted immunotherapies to treat cancer and infectious diseases, has announced a collaboration agreement …
NICE backs Celgene’s Otezla for psoriatic arthritis
October 12, 2016Research and Development, Sales and Marketing Celgene, NICE, otezla
The national Institute of Health and Care Excellence has issued recommendation of Celgene’s Otezla (apremilast) for the treatment of psoriatic …
AstraZeneca forced to abandon Phase II trial
October 12, 2016Research and Development AstraZeneca, Synairgen, asthma, cold, common cold
Synairgen, a respiratory drug discovery and development company, has developed a drug, AZD9412, alongside AstraZeneca to treat and prevent severe …
Sanofi appoint Alan Main to Executive Committee and Executive Vice President Consumer Healthcare
October 11, 2016Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing
Sanofi announced the appointment of Alan Main as Executive Vice President Consumer Healthcare effective October 1.Mr Main, who previously worked …
Exelixis’ Cabometyx smashes Pfizer cancer drug in Phase II trial
October 11, 2016Manufacturing and Production, Research and Development Cabometyx, Exelixis, Pfizer, Phase II, Sutent, advanced renal cell carcinoma
Phase II results presented by genomics-based discovery company Exelixis at the European Society for Medical Oncology (ESMO) congresss has put …
Nordic Nanovector and LegoChem Biosciences enter into collaboration
October 11, 2016Manufacturing and Production
The Norwegian company Nordic Nanovector and the South Korean company LegoChem Biosciences have begun a collaboration to develop novel CD37-targeting …
Takeda enters $790m cancer development deal
October 11, 2016Manufacturing and Production, Research and Development Cancer, Crescendo Biologics, Takeda, clinical partnership, humabody
Takeda and Crescendo Biologics have shaken hands on a $790 million deal to develop and commercialise cancer therapeutics using Crescendo’s …
Roche granted further good news by FDA
October 11, 2016Manufacturing and Production Actembra, Alecensa, FDA, Lucentis, Roche, United States, america
Roche was given further good news by FDA after receiving a Priority Review for its Lucentis drug – this news …
New UK & Ireland general manager for Teva
October 10, 2016Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Teva, appointment
Kim Innes has been appointed by Teva as its new general manager of UK & Ireland. Innes succeeds Richard Daniell, …
UAE’s pharmaceutical market projected to grow from $3 billion to $5.7 billion by 2020
October 10, 2016Manufacturing and Production Abu Dhabi, Dubai, GlobalData, United Arab Emires, growth, medical tourism, pharmaceutical market
United Arab Emirates’ pharmaceutical market is set for growth of 13% annually to reach $5.7 billion by 2020, up from …
Educating pharma
October 10, 2016Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing educated, funding, medical education, transparency
Originally published in the October issue of Pharmafocus, Sean Murray takes a look at how pharma continues to occupy a key …
Failure for BMS’ Opdivo in lung cancer trial
October 10, 2016Research and Development, Sales and Marketing BMS, MSD, Roche, clinical trial failure, keytruda, opdivo, tecentriq
Disappointing news for Bristol-Myers Squibb as the company announced that its blockbuster drug Opdivo (nivolumab) failed to meet its primary …
Roche’s lung cancer success spells competition for BMS’ Opdivo
October 10, 2016Research and Development, Sales and Marketing BMS, Roche, lung cancer, opdivo, tecentriq
Roche’s immune-system booster drug Tecentriq (atezolizumab) may cause trouble in the lung cancer field for leader Bristol-Myers Squibb’s Opdivo according …
MSD’s Keytruda twice as successful against standard therapy for lung cancer
October 10, 2016Sales and Marketing Bristol-Myers Squibb, MSD, Merck, keytruda
MSD, known as Merck in North America, released data that displayed the success of their drug, Keytruda, in a 123-patient …
Mylan agrees $465m settlement over EpiPen misclassification
October 10, 2016Business Services, Medical Communications, Sales and Marketing Heather Bresch, Mylan, Price hike, epipen
In the latest scandal in the EpiPen price hike saga, the US Department of Justice has made claims that the …
Novartis’ new drug muscles in on Pfizer’s territory
October 10, 2016Sales and Marketing Eli Lilly, Novartis, Pfizer, ibrance, ribociclib
A drug developed by Novartis, ribociclib, when combined with an older drug, letrozole, has been shown to reduce risk of progression …
Latest content
Report highlights scope to expand day surgery
Sygnature formalises drug discovery collaboration with X-Chem
Codis appoints Steven Facer as chief commercial officer
Danish medical cannabis use rises as regulator reports no new safety signals
